The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients

International Journal of Molecular Sciences

Volumn 16, Issue 10, 2015, Pages 24243-24275

  Egeland, Nina G ^a,b   Lunde, Siri ^a   Jonsdottir, Kristin ^a   Lende, Tone H ^a,c   Cronin Fenton, Deirdre ^d   Gilje, Bjørnar ^a   Janssen, Emiel A M ^a,b   Søiland, Håvard ^a,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF STAVANGER   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Biomarker; Breast cancer; Endocrine resistance; MicroRNA; Tamoxifen

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 10A; MICRORNA 126A; MICRORNA 210; MICRORNA 26; MICRORNA 26A; MICRORNA 30A 3P; MICRORNA 30C; MICRORNA 342; MICRORNA 519A; PHOSPHATIDYLINOSITOL 3 KINASE; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER TISSUE; CLINICAL TRIAL (TOPIC); DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; MEDICAL LITERATURE; NONHUMAN; PUBLICATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84945242997     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161024243     Document Type: Review

References (120)

1. Haynes, B.P.; Viale, G.; Galimberti, V.; Rotmensz, N.; Gibelli, B.; A'Hern, R.; Smith, I.E.; Dowsett, M. Expression of key estrogen-regulated genes differs substantially across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast Cancer Res. Treat. 2013, 138, 157-165
2. Baak, J.P.A.; van Diest, P.J.; Voorhorst, F.J.; van der Wall, E.; Beex, L.V.A.M.; Vermorken, J.B.; Janssen, E.A.M.; Gudlaugsson, E.; other collaborators of the Multicenter Morphometric Mammary Carcinoma Project (MMMCP). The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur. J. Cancer 2007, 43, 527-535
3. Goldhirsch, A.; Winer, E.P.; Coates, A.S.; Gelber, R.D.; Piccart-Gebhart, M.; Thurlimann, B.; Senn, H.J. Personalizing the treatment of women with early breast cancer: Highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann. Oncol. 2013, 24, 2206-2223
4. Cuzick, J.; Dowsett, M.; Pineda, S.; Wale, C.; Salter, J.; Quinn, E.; Zabaglo, L.; Mallon, E.; Green, A.R.; Ellis, I.O.; et al. Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J. Clin. Oncol. 2011, 29, 4273-4278
5. National Comprehensive Cancer Network (NCCN). Available online: http://www.nccn.org/(accessed on 4 October 2015)
6. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Early breast cancer trialists’ collaborative group. Lancet 1998, 351, 1451-1467
7. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365, 1687-1717
8. Carlson, R.W.; Allred, D.C.; Anderson, B.O.; Burstein, H.J.; Carter, W.B.; Edge, S.B.; Erban, J.K.; Farrar, W.B.; Forero, A.; Giordano, S.H.; et al. Invasive breast cancer, clinical practice guidelines, NCCN. J. Natl. Compr. Cancer Netw. 2011, 9, 136-222
9. Burstein, H.J.; Prestrud, A.A.; Seidenfeld, J.; Anderson, H.; Buchholz, T.A.; Davidson, N.E.; Gelmon, K.E.; Giordano, S.H.; Hudis, C.A.; Malin, J.; et al. American society of clinical oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 2010, 28, 3784-3796
10. Gnant, M.; Harbeck, N.; Thomssen, C. St. Gallen 2011: Summary of the consensus discussion. Breast Care 2011, 6, 136-141
11. Musgrove, E.A.; Sutherland, R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009, 9, 631-643
12. Dos Anjos Pultz, B.; da Luz, F.A.; de Faria, P.R.; Oliveira, A.P.; de Araujo, R.A.; Silva, M.J. Far beyond the usual biomarkers in breast cancer: A review. J. Cancer 2014, 5, 559-571
13. Guo, H.; Ingolia, N.T.; Weissman, J.S.; Bartel, D.P. Mammalian micrornas predominantly act to decrease target mrna levels. Nature 2010, 466, 835-840
14. Kuiper, G.G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138, 863-870
15. Paech, K.; Webb, P.; Kuiper, G.G.; Nilsson, S.; Gustafsson, J.; Kushner, P.J.; Scanlan, T.S. Differential ligand activation of estrogen receptors eralpha and erbeta at ap1 sites. Science 1997, 277, 1508-1510
16. Russo, J.; Russo, I.H. Genotoxicity of steroidal estrogens. Trends Endocrinol. Metab. 2004, 15, 211-214
17. Tsai, M.J.; O’Malley, B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63, 451-486
18. Davies, C.; Pan, H.; Godwin, J.; Gray, R.; Arriagada, R.; Raina, V.; Abraham, M.; Alencar, V.H.M.; Badran, A.; Bonfill, X.; et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: Atlas, a randomised trial. Lancet 2013, 381, 805-816
19. Hayes, E.L.; Lewis-Wambi, J.S. Mechanisms of endocrine resistance in breast cancer: An overview of the proposed roles of noncoding RNA. Breast Cancer Res. 2015, 17, 40
20. Fisher, B.; Costantino, J.P.; Wickerham, D.L.; Cecchini, R.S.; Cronin, W.M.; Robidoux, A.; Bevers, T.B.; Kavanah, M.T.; Atkins, J.N.; Margolese, R.G.; et al. Tamoxifen for the prevention of breast cancer: Current status of the national surgical adjuvant breast and bowel project p-1 study. J. Natl. Cancer Inst. 2005, 97, 1652-1662
21. Ellis, P.A.; Saccani-Jotti, G.; Clarke, R.; Johnston, S.R.; Anderson, E.; Howell, A.; A’Hern, R.; Salter, J.; Detre, S.; Nicholson, R.; et al. Induction of apoptosis by tamoxifen and ici 182780 in primary breast cancer. Int. J. Cancer 1997, 72, 608-613
22. Deligdisch, L.; Kalir, T.; Cohen, C.J.; de Latour, M.; Le Bouedec, G.; Penault-Llorca, F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol. Oncol. 2000, 78, 181-186
23. Heldring, N.; Pike, A.; Andersson, S.; Matthews, J.; Cheng, G.; Hartman, J.; Tujague, M.; Strom, A.; Treuter, E.; Warner, M.; et al. Estrogen receptors: How do they signal and what are their targets. Physiol. Rev. 2007, 87, 905-931
24. Norwegian Breast Cancer Group (NBCG). Available online: http://nbcg.no/ (accessed on 4 October 2015)
25. Nass, N.; Kalinski, T. Tamoxifen resistance: From cell culture experiments towards novel biomarkers. Pathology 2015, 211, 189-197
26. Hoskins, J.M.; Carey, L.A.; McLeod, H.L. Cyp2d6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 2009, 9, 576-586
27. Srinivasan, M.; Sedmak, D.; Jewell, S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 2002, 161, 1961-1971
28. Gjerde, J.; Geisler, J.; Lundgren, S.; Ekse, D.; Varhaug, J.E.; Mellgren, G.; Steen, V.M.; Lien, E.A. Associations between tamoxifen, estrogens, and fsh serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 2010, 10, 313
29. Cronin-Fenton, D.P.; Damkier, P.; Lash, T.L. Metabolism and transport of tamoxifen in relation to its effectiveness: New perspectives on an ongoing controversy. Future Oncol. 2014, 10, 107-122
30. Lien, E.A.; Soiland, H.; Lundgren, S.; Aas, T.; Steen, V.M.; Mellgren, G.; Gjerde, J. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res. Treat. 2013, 141, 243-248
31. Geisler, J.; Lonning, P.E. Aromatase inhibition: Translation into a successful therapeutic approach. Clin. Cancer Res. 2005, 11, 2809-2821
32. Dowsett, M.; Jones, A.; Johnston, S.R.; Jacobs, S.; Trunet, P.; Smith, I.E. In vivo measurement of aromatase inhibition by letrozole (cgs 20267) in postmenopausal patients with breast cancer. Clin. Cancer Res. 1995, 1, 1511-1515
33. Geisler, J.; Haynes, B.; Anker, G.; Dowsett, M.; Lonning, P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 2002, 20, 751-757
34. Forbes, J.F.; Cuzick, J.; Buzdar, A.; Howell, A.; Tobias, J.S.; Baum, M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the atac trial. Lancet Oncol. 2008, 9, 45-53
35. Mouridsen, H.; Giobbie-Hurder, A.; Goldhirsch, A.; Thurlimann, B.; Paridaens, R.; Smith, I.; Mauriac, L.; Forbes, J.; Price, K.N.; Regan, M.M.; et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 2009, 361, 766-776
36. Osborne, C.K.; Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 2011, 62, 233-247
37. Viedma-Rodriguez, R.; Baiza-Gutman, L.; Salamanca-Gomez, F.; Diaz-Zaragoza, M.; Martinez-Hernandez, G.; Ruiz Esparza-Garrido, R.; Velazquez-Flores, M.A.; Arenas-Aranda, D. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol. Rep. 2014, 32, 3-15
38. Garcia-Becerra, R.; Santos, N.; Diaz, L.; Camacho, J. Mechanisms of resistance to endocrine therapy in breast cancer: Focus on signaling pathways, mirnas and genetically based resistance. Int. J. Mol. Sci. 2012, 14, 108-145
39. Miller, W.R. Biological rationale for endocrine therapy in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2004, 18, 1-32
40. Mirbase: The Microrna Database. Available online: http://www.mirbase.org/index.shtml (accessed on 4 October 2015)
41. Griffiths-Jones, S.; Grocock, R.J.; van Dongen, S.; Bateman, A.; Enright, A.J. Mirbase: Microrna sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, 34, D140-D144
42. Kozomara, A.; Griffiths-Jones, S. Mirbase: Annotating high confidence micrornas using deep sequencing data. Nucleic Acids Res. 2014, 42, D68-D73
43. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; et al. Frequent deletions and down-regulation of micro- rna genes mir15 and mir16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 15524-15529
44. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; et al. Human microrna genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999-3004
45. Zhang, B.; Pan, X.; Cobb, G.P.; Anderson, T.A. Micrornas as oncogenes and tumor suppressors. Dev. Biol. 2007, 302, 1-12
46. Cittelly, D.M.; Das, P.M.; Spoelstra, N.S.; Edgerton, S.M.; Richer, J.K.; Thor, A.D.; Jones, F.E. Downregulation of mir-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer 2010, 9, 317
47. Hoppe, R.; Achinger-Kawecka, J.; Winter, S.; Fritz, P.; Lo, W.Y.; Schroth, W.; Brauch, H. Increased expression of mir-126 and mir-10a predict prolonged relapse-free time of primary estrogen receptor-positive breast cancer following tamoxifen treatment. Eur. J. Cancer 2013, 49, 3598-3608
48. Ward, A.; Shukla, K.; Balwierz, A.; Soons, Z.; Konig, R.; Sahin, O.; Wiemann, S. Microrna-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J. Pathol. 2014, 233, 368-379
49. Rodriguez-Gonzalez, F.G.; Sieuwerts, A.M.; Smid, M.; Look, M.P.; Meijer-van Gelder, M.E.; de Weerd, V.; Sleijfer, S.; Martens, J.W.; Foekens, J.A. Microrna-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 2011, 127, 43-51
50. Rothe, F.; Ignatiadis, M.; Chaboteaux, C.; Haibe-Kains, B.; Kheddoumi, N.; Majjaj, S.; Badran, B.; Fayyad-Kazan, H.; Desmedt, C.; Harris, A.L.; et al. Global microrna expression profiling identifies mir-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 2011, 6, e20980
51. Jansen, M.P.; Reijm, E.A.; Sieuwerts, A.M.; Ruigrok-Ritstier, K.; Look, M.P.; Rodriguez-Gonzalez, F.G.; Heine, A.A.; Martens, J.W.; Sleijfer, S.; Foekens, J.A.; et al. High mir-26a and low cdc2 levels associate with decreased ezh2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res. Treat. 2012, 133, 937-947
52. Van Schooneveld, E.; Wildiers, H.; Vergote, I.; Vermeulen, P.B.; Dirix, L.Y.; van Laere, S.J. Dysregulation of micrornas in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015, 17, 21
53. Iorio, M.V.; Ferracin, M.; Liu, C.G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; et al. Microrna gene expression deregulation in human breast cancer. Cancer Res. 2005, 65, 7065-7070
54. Sempere, L.F.; Christensen, M.; Silahtaroglu, A.; Bak, M.; Heath, C.V.; Schwartz, G.; Wells, W.; Kauppinen, S.; Cole, C.N. Altered microrna expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67, 11612-11620
55. Yan, L.X.; Huang, X.F.; Shao, Q.; Huang, M.Y.; Deng, L.; Wu, Q.L.; Zeng, Y.X.; Shao, J.Y. Microrna mir-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14, 2348-2360
56. Yan, L.X.; Wu, Q.N.; Zhang, Y.; Li, Y.Y.; Liao, D.Z.; Hou, J.H.; Fu, J.; Zeng, M.S.; Yun, J.P.; Wu, Q.L.; et al. Knockdown of mir-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 2011, 13, R2
57. Li, H.; Bian, C.; Liao, L.; Li, J.; Zhao, R.C. Mir-17-5p promotes human breast cancer cell migration and invasion through suppression of hbp1. Breast Cancer Res. Treat. 2011, 126, 565-575
58. Leivonen, S.K.; Makela, R.; Ostling, P.; Kohonen, P.; Haapa-Paananen, S.; Kleivi, K.; Enerly, E.; Aakula, A.; Hellstrom, K.; Sahlberg, N.; et al. Protein lysate microarray analysis to identify micrornas regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009, 28, 3926-3936
59. Jonsdottir, K.; Janssen, S.R.; Da Rosa, F.C.; Gudlaugsson, E.; Skaland, I.; Baak, J.P.; Janssen, E.A. Validation of expression patterns for nine mirnas in 204 lymph-node negative breast cancers. PLoS ONE 2012, 7, e48692
60. Calvano Filho, C.M.; Calvano-Mendes, D.C.; Carvalho, K.C.; Maciel, G.A.; Ricci, M.D.; Torres, A.P.; Filassi, J.R.; Baracat, E.C. Triple-negative and luminal a breast tumors: Differential expression of mir-18a-5p, mir-17-5p, and mir-20a-5p. Tumour Biol. 2014, 35, 7733-7741
61. Nilsson, S.; Moller, C.; Jirstrom, K.; Lee, A.; Busch, S.; Lamb, R.; Landberg, G. Downregulation of mir-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS ONE 2012, 7, e36051
62. Hunter, M.P.; Ismail, N.; Zhang, X.; Aguda, B.D.; Lee, E.J.; Yu, L.; Xiao, T.; Schafer, J.; Lee, M.L.; Schmittgen, T.D.; et al. Detection of microrna expression in human peripheral blood microvesicles. PLoS ONE 2008, 3, e3694
63. Stuckrath, I.; Rack, B.; Janni, W.; Jager, B.; Pantel, K.; Schwarzenbach, H. Aberrant plasma levels of circulating mir-16, mir-107, mir-130a and mir-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget 2015, 6, 13387
64. Roth, C.; Rack, B.; Muller, V.; Janni, W.; Pantel, K.; Schwarzenbach, H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010, 12, R90
65. Madhavan, D.; Zucknick, M.; Wallwiener, M.; Cuk, K.; Modugno, C.; Scharpff, M.; Schott, S.; Heil, J.; Turchinovich, A.; Yang, R.; et al. Circulating mirnas as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 2012, 18, 5972-5982
66. Cheng, L.; Sharples, R.A.; Scicluna, B.J.; Hill, A.F. Exosomes provide a protective and enriched source of mirna for biomarker profiling compared to intracellular and cell-free blood. J. Extracell. Vesicles 2014, 3, doi:10.3402/jev.v3.23743
67. Kosaka, N.; Yoshioka, Y.; Hagiwara, K.; Tominaga, N.; Ochiya, T. Functional analysis of exosomal microrna in cell-cell communication research. Methods Mol. Biol. 2013, 1024, 1-10
68. Taylor, D.D.; Black, P.H. Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev. Biol. 1986, 3, 33-57
69. Zhao, L.; Liu, W.; Xiao, J.; Cao, B. The role of exosomes and “exosomal shuttle microrna” in tumorigenesis and drug resistance. Cancer Lett. 2015, 356, 339-346
70. Chen, W.X.; Liu, X.M.; Lv, M.M.; Chen, L.; Zhao, J.H.; Zhong, S.L.; Ji, M.H.; Hu, Q.; Luo, Z.; Wu, J.Z.; et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of micrornas. PLoS ONE 2014, 9, e95240
71. Wei, Y.; Lai, X.; Yu, S.; Chen, S.; Ma, Y.; Zhang, Y.; Li, H.; Zhu, X.; Yao, L.; Zhang, J. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res. Treat. 2014, 147, 423-431
72. Reijm, E.A.; Jansen, M.P.; Ruigrok-Ritstier, K.; van Staveren, I.L.; Look, M.P.; van Gelder, M.E.; Sieuwerts, A.M.; Sleijfer, S.; Foekens, J.A.; Berns, E.M. Decreased expression of ezh2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res. Treat. 2011, 125, 387-394
73. Johnson, N.; Bentley, J.; Wang, L.Z.; Newell, D.R.; Robson, C.N.; Shapiro, G.I.; Curtin, N.J. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br. J. Cancer 2010, 102, 342-350
74. Bosco, E.E.; Wang, Y.; Xu, H.; Zilfou, J.T.; Knudsen, K.E.; Aronow, B.J.; Lowe, S.W.; Knudsen, E.S. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J. Clin. Investig. 2007, 117, 218-228
75. Dupont, J.; Le Roith, D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of mcf-7 breast cancer cells: New insights into their synergistic effects. Mol. Pathol. 2001, 54, 149-154
76. Riedemann, J.; Macaulay, V.M. Igf1r signalling and its inhibition. Endocr. Relat. Cancer 2006, 13, S33-S43
77. Fagan, D.H.; Yee, D. Crosstalk between igf1r and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13, 423-429
78. Chen, H.X.; Sharon, E. Igf-1r as an anti-cancer target-Trials and tribulations. Chin. J. Cancer 2013, 32, 242-252
79. Planas-Silva, M.D.; Hamilton, K.N. Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother. Pharmacol. 2007, 60, 535-543
80. Morgan, L.; Gee, J.; Pumford, S.; Farrow, L.; Finlay, P.; Robertson, J.; Ellis, I.; Kawakatsu, H.; Nicholson, R.; Hiscox, S. Elevated src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol. Ther. 2009, 8, 1550-1558
81. Larsen, S.L.; Laenkholm, A.V.; Duun-Henriksen, A.K.; Bak, M.; Lykkesfeldt, A.E.; Kirkegaard, T. Src drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment. PLoS ONE 2015, 10, e0118346
82. Ignatov, A.; Ignatov, T.; Weissenborn, C.; Eggemann, H.; Bischoff, J.; Semczuk, A.; Roessner, A.; Costa, S.D.; Kalinski, T. G-protein-coupled estrogen receptor gpr30 and tamoxifen resistance in breast cancer. Breast Cancer Res. Treat. 2011, 128, 457-466
83. Yuan, J.; Liu, M.; Yang, L.; Tu, G.; Zhu, Q.; Chen, M.; Cheng, H.; Luo, H.; Fu, W.; Li, Z.; et al. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: A new role for g protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and beta1-integrin signaling pathway in tumor cells. Breast Cancer Res. 2015, 17, 69
84. Mahajan, K.; Lawrence, H.R.; Lawrence, N.J.; Mahajan, N.P. Ack1 tyrosine kinase interacts with histone demethylase kdm3a to regulate the mammary tumor oncogene hoxa1. J. Biol. Chem. 2014, 289, 28179-28191
85. Mahajan, K.; Mahajan, N.P. Ack1/tnk2 tyrosine kinase: Molecular signaling and evolving role in cancers. Oncogene 2014, 34, 4162-4167
86. Lianos, G.D.; Alexiou, G.A.; Mangano, A.; Mangano, A.; Rausei, S.; Boni, L.; Dionigi, G.; Roukos, D.H. The role of heat shock proteins in cancer. Cancer Lett. 2015, 360, 114-118
87. Zhao, R.; Leung, E.; Gruner, S.; Schapira, M.; Houry, W.A. Tamoxifen enhances the hsp90 molecular chaperone atpase activity. PLoS ONE 2010, 5, e9934
88. Whitesell, L.; Santagata, S.; Mendillo, M.L.; Lin, N.U.; Proia, D.A.; Lindquist, S. Hsp90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proc. Natl. Acad. Sci. USA 2014, 111, 18297-18302
89. Hurtado, A.; Holmes, K.A.; Ross-Innes, C.S.; Schmidt, D.; Carroll, J.S. Foxa1 is a critical determinant of estrogen receptor function and endocrine response. Nat. Genet. 2011, 43, 27-33
90. Ross-Innes, C.S.; Stark, R.; Teschendorff, A.E.; Holmes, K.A.; Ali, H.R.; Dunning, M.J.; Brown, G.D.; Gojis, O.; Ellis, I.O.; Green, A.R.; et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481, 389-393
91. Pruitt, K.D.; Brown, G.R.; Hiatt, S.M.; Thibaud-Nissen, F.; Astashyn, A.; Ermolaeva, O.; Farrell, C.M.; Hart, J.; Landrum, M.J.; McGarvey, K.M.; et al. Refseq: An update on mammalian reference sequences. Nucleic Acids Res. 2014, 42, D756-D763
92. Lundqvist, J.; Yde, C.W.; Lykkesfeldt, A.E. 1alpha,25-dihydroxyvitamin d3 inhibits cell growth and nfkappab signaling in tamoxifen-resistant breast cancer cells. Steroids 2014, 85, 30-35
93. Gan, R.; Yang, Y.; Yang, X.; Zhao, L.; Lu, J.; Meng, Q.H. Downregulation of mir-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of timp3. Cancer Gene Ther. 2014, 21, 290-296
94. Zhao, L.; Vogt, P.K. Class i pi3k in oncogenic cellular transformation. Oncogene 2008, 27, 5486-5496
95. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase (pi3k) pathway in cancer. Nat. Rev. Drug Discov. 2009, 8, 627-644
96. Sabine, V.S.; Crozier, C.; Brookes, C.L.; Drake, C.; Piper, T.; van de Velde, C.J.; Hasenburg, A.; Kieback, D.G.; Markopoulos, C.; Dirix, L.; et al. Mutational analysis of pi3k/akt signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J. Clin. Oncol. 2014, 32, 2951-2958
97. Miller, T.W.; Rexer, B.N.; Garrett, J.T.; Arteaga, C.L. Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011, 13, 224
98. Juric, D.; Castel, P.; Griffith, M.; Griffith, O.L.; Won, H.H.; Ellis, H.; Ebbesen, S.H.; Ainscough, B.J.; Ramu, A.; Iyer, G.; et al. Convergent loss of pten leads to clinical resistance to a pi(3)kalpha inhibitor. Nature 2015, 518, 240-244
99. Ujihira, T.; Ikeda, K.; Suzuki, T.; Yamaga, R.; Sato, W.; Horie-Inoue, K.; Shigekawa, T.; Osaki, A.; Saeki, T.; Okamoto, K.; et al. Microrna-574-3p, identified by microrna library-based functional screening, modulates tamoxifen response in breast cancer. Sci. Rep. 2015, 5, 7641
100. Manavalan, T.T.; Teng, Y.; Litchfield, L.M.; Muluhngwi, P.; Al-Rayyan, N.; Klinge, C.M. Reduced expression of mir-200 family members contributes to antiestrogen resistance in ly2 human breast cancer cells. PLoS ONE 2013, 8, e62334
101. Cittelly, D.M.; Das, P.M.; Salvo, V.A.; Fonseca, J.P.; Burow, M.E.; Jones, F.E. Oncogenic her2 delta 16 suppresses mir-15a/16 and deregulates bcl-2 to promote endocrine resistance of breast tumors. Carcinogenesis 2010, 31, 2049-2057
102. Lash, T.L.; Lien, E.A.; Sorensen, H.T.; Hamilton-Dutoit, S. Genotype-guided tamoxifen therapy: Time to pause for reflection? Lancet Oncol. 2009, 10, 825-833
103. Lonning, P.E. Molecular basis for therapy resistance. Mol. Oncol. 2010, 4, 284-300
104. Russnes, H.G.; Navin, N.; Hicks, J.; Borresen-Dale, A.L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J. Clin. Investig. 2011, 121, 3810-3818
105. Flageng, M.H.; Moi, L.L.; Dixon, J.M.; Geisler, J.; Lien, E.A.; Miller, W.R.; Lonning, P.E.; Mellgren, G. Nuclear receptor co-activators and her-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br. J. Cancer 2009, 101, 1253-1260
106. Moi, L.L.; Flageng, M.H.; Gjerde, J.; Madsen, A.; Rost, T.H.; Gudbrandsen, O.A.; Lien, E.A.; Mellgren, G. Steroid receptor coactivators, her-2 and her-3 expression is stimulated by tamoxifen treatment in dmba-induced breast cancer. BMC Cancer 2012, 12, 247
107. Creighton, C.J.; Fu, X.; Hennessy, B.T.; Casa, A.J.; Zhang, Y.; Gonzalez-Angulo, A.M.; Lluch, A.; Gray, J.W.; Brown, P.H.; Hilsenbeck, S.G.; et al. Proteomic and transcriptomic profiling reveals a link between the pi3k pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010, 12, R40
108. Fu, X.; Creighton, C.J.; Biswal, N.C.; Kumar, V.; Shea, M.; Herrera, S.; Contreras, A.; Gutierrez, C.; Wang, T.; Nanda, S.; et al. Overcoming endocrine resistance due to reduced pten levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase b, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014, 16, 430
109. Goh, J.N.; Loo, S.Y.; Datta, A.; Siveen, K.S.; Yap, W.N.; Cai, W.; Shin, E.M.; Wang, C.; Kim, J.E.; Chan, M.; et al. Micrornas in breast cancer: Regulatory roles governing the hallmarks of cancer. Biol. Rev. Camb. Philos. Soc. 2015, doi:10.1111/brv.12176
110. Volinia, S.; Galasso, M.; Sana, M.E.; Wise, T.F.; Palatini, J.; Huebner, K.; Croce, C.M. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc. Natl. Acad. Sci. USA 2012, 109, 3024-3029
111. Tan, S.; Ding, K.; Li, R.; Zhang, W.; Li, G.; Kong, X.; Qian, P.; Lobie, P.E.; Zhu, T. Identification of mir-26 as a key mediator of estrogen stimulated cell proliferation by targeting chd1, greb1 and kpna2. Breast Cancer Res. 2014, 16, R40
112. Zhang, J.; Du, Y.Y.; Lin, Y.F.; Chen, Y.T.; Yang, L.; Wang, H.J.; Ma, D. The cell growth suppressor, mir-126, targets irs-1. Biochem. Biophys. Res. Commun. 2008, 377, 136-140
113. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T.; et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351, 2817-2826
114. Albain, K.S.; Paik, S.; van’t Veer, L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009, 18, S141-S145
115. Engstrom, M.J.; Opdahl, S.; Hagen, A.I.; Romundstad, P.R.; Akslen, L.A.; Haugen, O.A.; Vatten, L.J.; Bofin, A.M. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res. Treat. 2013, 140, 463-473
116. Cheng, Q.; Chang, J.T.; Gwin, W.R.; Zhu, J.; Ambs, S.; Geradts, J.; Lyerly, H.K. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Res. 2014, 16, 407
117. Lo, A.C.; Truong, P.T.; Wai, E.S.; Nichol, A.; Weir, L.; Speers, C.; Hayes, M.M.; Baliski, C.; Tyldesley, S. Population-based analysis of the impact and generalizability of the nsabp-b24 study on endocrine therapy for patients with ductal carcinoma in situ of the breastdagger. Ann. Oncol. 2015, doi:10.1093/annonc/mdv251
118. Bernhard, J.; Luo, W.; Ribi, K.; Colleoni, M.; Burstein, H.J.; Tondini, C.; Pinotti, G.; Spazzapan, S.; Ruhstaller, T.; Puglisi, F.; et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (text and soft): A combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015, 16, 848-858
119. Soiland, H.; Hagen, K.B.; Gjerde, J.; Lende, T.H.; Lien, E.A. Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in scandinavian breast cancer patients. Acta Oncol. 2013, 52, 861-862
120. Lintermans, A.; Neven, P. Safety of aromatase inhibitor therapy in breast cancer. Expert Opin. Drug Saf. 2015, 1-11